Association between physical activity and dementia’s risk factors in patients with Parkinson’s disease
Autor: | Paola Imbriani, Nicola Biagio Mercuri, Donatella Franco, Paola Sinibaldi Salimei, Tommaso Schirinzi, Giulia Di Lazzaro, Antonio Pisani, Mohammad Alwardat, Sergio Bernardini, Giulia Maria Sancesario |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Neurology Parkinson's disease Parkinson’s disease dementia tau Proteins Disease 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine mental disorders CSF biomarkers Frailty Neuroprotection Parkinson’s disease Physical activity medicine Humans Dementia Exercise Biological Psychiatry Aged Amyloid beta-Peptides business.industry Confounding Neurodegeneration Parkinson Disease Middle Aged medicine.disease Symptomatic relief nervous system diseases Psychiatry and Mental health Cross-Sectional Studies 030104 developmental biology Mood disorders alpha-Synuclein Female Settore MED/26 - Neurologia Neurology (clinical) business Biomarkers 030217 neurology & neurosurgery |
Zdroj: | Journal of Neural Transmission. 126:319-325 |
ISSN: | 1435-1463 0300-9564 |
Popis: | Evidence suggests that physical activity (PA) exerts beneficial effects on neurodegenerative processes, either as symptomatic relief or disease-modifying strategy. Actually, it may represent a viable neuroprotective intervention in Parkinson's disease dementia (PDD), a severe, frequent, and untreatable complication of Parkinson's disease (PD). According to such hypothesis, this cross-sectional study tested, in PD patients, the association between levels of PA and well-known risk factors for PDD, such as mood disorders and amyloid-β42 CSF content. Amount of PA was measured by the International Physical Activity Questionnaires-Short Form (IPAQ-SF) in 128 cognitively intact PD patients and correlated with the Hamilton-Depression (HAM-D) and the Hamilton-Anxiety (HAM-A) scores; in a homogenous subgroup of 40 patients, it was further correlated with a panel of CSF biomarkers, including amyloid-β42, total α-synuclein, total, and phosphorylated tau. The statistical model was corrected for the main potential confounding factors (motor impairment, dopaminergic treatment, disease duration, age, and sex). Both the HAM-A and HAM-D scores, as well as the Aβ42 CSF content, improved in parallel with the increase of the total week amount of PA. Although with several limitations, we preliminarily demonstrated that a high level of PA is associated with a more favourable profile of PDD risk factors, in terms of both mood disturbances and CSF markers of neurodegeneration. However, confirmative studies are necessary to validate the efficacy of PA as protective intervention for PDD. |
Databáze: | OpenAIRE |
Externí odkaz: |